Dorval Allison 4
4 · Verve Therapeutics, Inc. · Filed Apr 3, 2025
Insider Transaction Report
Form 4
Dorval Allison
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-04-01+11,250→ 16,630 total - Sale
Common Stock
2025-04-02$4.15/sh−3,350$13,903→ 13,280 total - Exercise/Conversion
Restricted Stock Units
2025-04-01−11,250→ 33,750 total→ Common Stock (11,250 underlying)
Footnotes (3)
- [F1]Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.
- [F2]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on March 20, 2023, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
- [F3]On February 14, 2024, the reporting person was granted 45,000 RSUs pursuant to the Verve Therapeutics, Inc. 2021 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on April 1, 2025 and the remainder vesting in equal annual installments until April 1, 2028.